{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:59:08Z","timestamp":1793336348016,"version":"4.5.0"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32401159"],"award-info":[{"award-number":["32401159"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022963","name":"Key Research and Development Program of Zhejiang Province","doi-asserted-by":"publisher","award":["2025C01129"],"award-info":[{"award-number":["2025C01129"]}],"id":[{"id":"10.13039\/100022963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["QKHM25B0502"],"award-info":[{"award-number":["QKHM25B0502"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC3600902"],"award-info":[{"award-number":["2022YFC3600902"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.bcp.2026.117791","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T19:53:33Z","timestamp":1771358013000},"page":"117791","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["From 2020 to 2025: Comprehensive review Decoding novel structural inhibitors for Mpro of SARS-CoV-2"],"prefix":"10.1016","volume":"248","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8868-8350","authenticated-orcid":false,"given":"Xin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunzhi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3368-159X","authenticated-orcid":false,"given":"Xiaolin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bcp.2026.117791_b0005","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.bcp.2026.117791_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2020.104260","article-title":"Genetic diversity and evolution of SARS-CoV-2","volume":"81","author":"Phan","year":"2020","journal-title":"Infect. Genet. Evol."},{"issue":"4","key":"10.1016\/j.bcp.2026.117791_b0015","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.chom.2015.09.013","article-title":"MERS, SARS, and Ebola: the Role of Super-Spreaders in Infectious Disease","volume":"18","author":"Wong","year":"2015","journal-title":"Cell Host Microbe"},{"issue":"1","key":"10.1016\/j.bcp.2026.117791_b0020","doi-asserted-by":"crossref","first-page":"35","DOI":"10.18683\/germs.2019.1155","article-title":"Middle East respiratory syndrome coronavirus (MERS-CoV): a review","volume":"9","author":"Ramadan","year":"2019","journal-title":"Germs"},{"issue":"7811","key":"10.1016\/j.bcp.2026.117791_b0025","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2026.117791_b0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","article-title":"Mechanisms of SARS-CoV-2 entry into cells","volume":"23","author":"Jackson","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"5626","key":"10.1016\/j.bcp.2026.117791_b0035","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1126\/science.1085658","article-title":"Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of Anti-SARS Drugs","volume":"300","author":"Anand","year":"2003","journal-title":"Science"},{"issue":"17","key":"10.1016\/j.bcp.2026.117791_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127377","article-title":"The SARS-CoV-2 main protease as drug target","volume":"30","author":"Ullrich","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2026.117791_b0045","doi-asserted-by":"crossref","DOI":"10.1038\/nrd.2015.37","article-title":"Coronaviruses-drug discovery and therapeutic options","volume":"15","author":"Zumla","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2026.117791_b0050","doi-asserted-by":"crossref","DOI":"10.1126\/science.abb4489","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","author":"Dai","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bcp.2026.117791_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102023","article-title":"Key dimer interface residues impact the catalytic activity of 3CLpro, the main protease of SARS-CoV-2","volume":"298","author":"Ferreira","year":"2022","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.117791_b0060","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41392-022-00884-5","article-title":"Structural biology of SARS-CoV-2: open the door for novel therapies","volume":"7","author":"Yan","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.117791_b0065","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1038\/s41467-020-16954-7","article-title":"Structural Plasticity of SARS-CoV-2 3CL Mpro active Site Cavity Revealed by Room Temperature X-Ray Crystallography","volume":"11","author":"Kneller","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.117791_b0070","article-title":"Stereospecific synthesis of N-protected statine and its analogues via chiral tetramic acid","volume":"1","author":"Jouin","year":"1987","journal-title":"J. Chem. Soc. Perkin Trans."},{"key":"10.1016\/j.bcp.2026.117791_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/0006-291X(92)91136-E","article-title":"HIV-1 protease inhibitors containing statine : Inhibitory potency and antiviral activity","volume":"188","author":"Fehrentz","year":"1992","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2026.117791_b0080","doi-asserted-by":"crossref","first-page":"8991","DOI":"10.1038\/s41598-024-59442-4","article-title":"Statine-based peptidomimetic compounds as inhibitors for SARS-CoV-2 main protease (SARS-CoV\u20112 Mpro)","volume":"14","author":"Azevedo","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2026.117791_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114046","article-title":"Design, synthesis and invitro evaluation of novel SARS-CoV-2 3CL(pro) covalent inhibitors","volume":"229","author":"Stille","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.117791_b0090","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41422-020-0356-z","article-title":"Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease","volume":"30","author":"Ma","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.bcp.2026.117791_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112711","article-title":"The development of Coronavirus 3C-like protease (3CLpro) inhibitors from 2010 to 2020","volume":"206","author":"Liu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.117791_b0100","article-title":"Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19","volume":"13","author":"Liu","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.117791_b0105","doi-asserted-by":"crossref","DOI":"10.1038\/s41422-020-0356-z","article-title":"Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease","volume":"30","author":"Ma","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.bcp.2026.117791_b0110","unstructured":"Sacco, M.D., et al., Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against Mpro and cathepsin L. Science Advances. 6(50): p. eabe0751."},{"issue":"4","key":"10.1016\/j.bcp.2026.117791_b0115","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1021\/acsptsci.1c00099","article-title":"Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir","volume":"4","author":"Xia","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"6536","key":"10.1016\/j.bcp.2026.117791_b0120","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1126\/science.abf1611","article-title":"SARS-CoV-2 M(pro) inhibitors with antiviral activity in a transgenic mouse model","volume":"371","author":"Qiao","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.bcp.2026.117791_b0125","unstructured":"Food and Drug Administration. Authorization for Paxlovid for Treatment of COVID-19. https:\/\/www.fda.gov\/media\/155052\/download."},{"issue":"23","key":"10.1016\/j.bcp.2026.117791_b0130","doi-asserted-by":"crossref","first-page":"13190","DOI":"10.1073\/pnas.1835675100","article-title":"The Crystal Structures of Severe Acute respiratory Syndrome Virus Main Protease and its complex with an Inhibitor","volume":"100","author":"Yang","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2026.117791_b0135","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An Oral SARS-CoV-2 Mpro Inhibitor Clinical Candidate for the Treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.bcp.2026.117791_b0140","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.omtn.2023.03.013","article-title":"Resistance to nirmatrelvir due to mutations in the Mpro in the subvariants of SARS-CoV-2 Omicron: another concern?","volume":"32","author":"Chatterjee","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"8","key":"10.1016\/j.bcp.2026.117791_b0145","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1021\/acscentsci.3c00538","article-title":"Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir","volume":"9","author":"Hu","year":"2023","journal-title":"ACS Cent. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.117791_b0150","doi-asserted-by":"crossref","first-page":"6463","DOI":"10.1038\/s41467-023-42102-y","article-title":"Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir","volume":"14","author":"Jiang","year":"2023","journal-title":"Nat. Commun."},{"issue":"16","key":"10.1016\/j.bcp.2026.117791_b0155","doi-asserted-by":"crossref","first-page":"13550","DOI":"10.1021\/acs.jmedchem.3c02469","article-title":"A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19","volume":"67","author":"Allerton","year":"2024","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.117791_b0160","doi-asserted-by":"crossref","first-page":"6503","DOI":"10.1038\/s41467-024-50931-8","article-title":"The small molecule inhibitor of SARS-CoV-2 3CLpro EDP-235 prevents viral replication and transmission in vivo","volume":"15","author":"Rhodin","year":"2024","journal-title":"Nat. Commun."},{"issue":"21","key":"10.1016\/j.bcp.2026.117791_b0165","doi-asserted-by":"crossref","first-page":"12725","DOI":"10.1021\/acs.jmedchem.0c01063","article-title":"Discovery of Ketone-based Covalent Inhibitors of Coronavirus 3CL Proteases for the potential Therapeutic Treatment of COVID-19","volume":"63","author":"Hoffman","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.117791_b0170","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.1038\/s41467-021-26239-2","article-title":"Preclinical Characterization of an Intravenous Coronavirus 3CL Protease Inhibitor for the potential Treatment of COVID19","volume":"12","author":"Boras","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.117791_b0175","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1039\/D1MD00247C","article-title":"Peptidomimetic Nitrile Warheads as SARS-CoV-2 3CL Protease Inhibitors","volume":"12","author":"Bai","year":"2021","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bcp.2026.117791_b0180","doi-asserted-by":"crossref","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.bcp.2026.117791_b0185","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41564-024-01618-9","article-title":"Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir","volume":"9","author":"Chen","year":"2024","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.bcp.2026.117791_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102189","article-title":"Antiviral efficacy of RAY1216 monotherapy and combination therapy with ritonavir in patients with COVID-19: a phase 2, single centre, randomised, double-blind, placebo-controlled trial","volume":"63","author":"Wang","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.bcp.2026.117791_b0195","doi-asserted-by":"crossref","unstructured":"Westberg, M., et al., An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations. Science Translational Medicine. 16(738): p. eadi0979.","DOI":"10.1126\/scitranslmed.adi0979"},{"issue":"5","key":"10.1016\/j.bcp.2026.117791_b0200","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1021\/acs.jmedchem.3c02248","article-title":"Invention of MK-7845, a SARS-CoV-2 3CL Protease Inhibitor Employing a Novel Difluorinated Glutamine Mimic","volume":"67","author":"Shurtleff","year":"2024","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2026.117791_b0205","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1021\/acs.jmedchem.3c01938","article-title":"Discovery of CMX990: a Potent SARS-CoV-2 3CL Protease Inhibitor Bearing a Novel Warhead","volume":"67","author":"Dayan Elshan","year":"2024","journal-title":"J. Med. Chem."},{"issue":"6497","key":"10.1016\/j.bcp.2026.117791_b0210","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.abb4489","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","volume":"368","author":"Dai","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bcp.2026.117791_b0215","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1038\/s41467-021-22362-2","article-title":"Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors","volume":"12","author":"Iketani","year":"2021","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.bcp.2026.117791_b0220","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1021\/acs.jmedchem.2c01627","article-title":"Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine","volume":"66","author":"Brewitz","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.117791_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115667","article-title":"Exploring diverse reactive warheads for the design of SARS-CoV-2 main protease inhibitors","volume":"259","author":"Tan","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.117791_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105450","article-title":"In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2","volume":"208","author":"Shang","year":"2022","journal-title":"Antiviral Res."},{"issue":"4","key":"10.1016\/j.bcp.2026.117791_b0235","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1021\/acs.jmedchem.1c00598","article-title":"Structure-based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CLpro)","volume":"65","author":"Han","year":"2022","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2026.117791_b0240","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1021\/jm301580n","article-title":"Discovery, Synthesis, and Structure-based Optimization of a Series of N -(Tert -Butyl)-2-(N -Arylamido)-2-(Pyridin-3-Yl) Acetamides (ML188) as Potent Noncovalent Small Molecule Inhibitors of the Severe Acute respiratory Syndrome Coronavirus (SARS-CoV) 3CL","volume":"56","author":"Jacobs","year":"2013","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bcp.2026.117791_b0245","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.chembiol.2021.05.018","article-title":"An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 Mpro inhibitor","volume":"28","author":"Zaidman","year":"2021","journal-title":"Cell Chem. Biol."},{"issue":"5","key":"10.1016\/j.bcp.2026.117791_b0250","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1021\/acsptsci.0c00108","article-title":"Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening","volume":"3","author":"Zhu","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"6557","key":"10.1016\/j.bcp.2026.117791_b0255","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1126\/science.abg5827","article-title":"Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2","volume":"373","author":"Drayman","year":"2021","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.bcp.2026.117791_b0260","doi-asserted-by":"crossref","DOI":"10.3390\/v13020174","article-title":"Crystal Structure of SARS-CoV-2 Main Protease in complex with the Non-Covalent Inhibitor ML188","volume":"13","author":"Lockbaum","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.bcp.2026.117791_b0265","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1021\/acs.jmedchem.1c00509","article-title":"Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors","volume":"65","author":"Kitamura","year":"2022","journal-title":"J. Med. Chem."},{"issue":"35","key":"10.1016\/j.bcp.2026.117791_b0270","doi-asserted-by":"crossref","first-page":"23555","DOI":"10.1039\/D3CP03828A","article-title":"The molecular mechanism of non-covalent inhibitor WU-04 targeting SARS-CoV-2 3CLpro and computational evaluation of its effectiveness against mainstream coronaviruses","volume":"25","author":"Wu","year":"2023","journal-title":"PCCP"},{"issue":"1","key":"10.1016\/j.bcp.2026.117791_b0275","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41421-024-00673-0","article-title":"Resistance mechanisms of SARS-CoV-2 3CLpro to the non-covalent inhibitor WU-04","volume":"10","author":"Zhang","year":"2024","journal-title":"Cell Discovery"},{"issue":"7","key":"10.1016\/j.bcp.2026.117791_b0280","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1021\/jacs.1c08402","article-title":"Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum activity against Coronaviruses","volume":"144","author":"Luttens","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bcp.2026.117791_b0285","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.str.2021.06.002","article-title":"Structure-Guided Design of a Perampanel-Derived Pharmacophore Targeting the SARS-CoV-2 Main Protease","volume":"29","author":"Deshmukh","year":"2021","journal-title":"Structure"},{"issue":"9","key":"10.1016\/j.bcp.2026.117791_b0290","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","article-title":"Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19","volume":"65","author":"Unoh","year":"2022","journal-title":"J. Med. Chem."},{"issue":"19","key":"10.1016\/j.bcp.2026.117791_b0295","doi-asserted-by":"crossref","first-page":"13343","DOI":"10.1021\/acs.jmedchem.2c01146","article-title":"Discovery and Crystallographic Studies of Trisubstituted Piperazine Derivatives as Non-Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity and Low Toxicity","volume":"65","author":"Gao","year":"2022","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bcp.2026.117791_b0300","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.str.2020.10.007","article-title":"Malleability of the SARS-CoV-2 3CL Mpro Active-Site Cavity Facilitates Binding of Clinical Antivirals","volume":"28","author":"Kneller","year":"2020","journal-title":"Structure"},{"issue":"23","key":"10.1016\/j.bcp.2026.117791_b0305","doi-asserted-by":"crossref","first-page":"17366","DOI":"10.1021\/acs.jmedchem.1c01475","article-title":"Structural, Electronic, and Electrostatic Determinants for Inhibitor Binding to Subsites S1 and S2 in SARS-CoV-2 Main Protease","volume":"64","author":"Kneller","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.117791_b0310","doi-asserted-by":"crossref","first-page":"20697","DOI":"10.1021\/jacs.1c08060","article-title":"Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity","volume":"143","author":"Ma","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bcp.2026.117791_b0315","doi-asserted-by":"crossref","unstructured":"Hattori, S.I., et al., GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection. mBio, 2020. 11: p. e01833-20.","DOI":"10.1128\/mBio.01833-20"},{"key":"10.1016\/j.bcp.2026.117791_b0320","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ijbiomac.2021.04.129","article-title":"Identification of Vitamin K3 and its analogues as covalent inhibitors of SARS-CoV-2 3CL(pro)","volume":"183","author":"Wang","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bcp.2026.117791_b0325","doi-asserted-by":"crossref","unstructured":"Detomasi, T.C., et al., Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus MPro inhibitors with potent in vivo efficacy. Science Advances. 11(17): p. eadt7836.","DOI":"10.1126\/sciadv.adt7836"},{"issue":"1","key":"10.1016\/j.bcp.2026.117791_b0330","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41392-023-01392-w","article-title":"A new generation Mpro inhibitor with potent activity against SARS-CoV-2 Omicron variants","volume":"8","author":"Huang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bcp.2026.117791_b0335","first-page":"473","volume":"24","author":"El Sayed","year":"2000","journal-title":"Natural Products as Antiviral Agents."},{"key":"10.1016\/j.bcp.2026.117791_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104939","article-title":"Review on the potential action mechanisms of chinese medicines in treating Coronavirus Disease 2019 (COVID-19)","volume":"158","author":"Huang","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2026.117791_b0345","doi-asserted-by":"crossref","unstructured":"Su, H., et al., Discovery of baicalin and baicalein as novel, natural product inhibitors of SARS-CoV-2 3CL protease in vitro. bioRxiv, 2020.","DOI":"10.1101\/2020.04.13.038687"},{"key":"10.1016\/j.bcp.2026.117791_b0350","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22137048","article-title":"Seleno-Functionalization of Quercetin Improves the Non-Covalent Inhibition of Mpro and its Antiviral activity in Cells against SARS-CoV-2","volume":"22","author":"Mangiavacchi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.bcp.2026.117791_b0355","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.scib.2020.10.018","article-title":"Crystal structure of SARS-CoV-2 main protease in complex with the natural product inhibitor shikonin illuminates a unique binding mode","volume":"66","author":"Li","year":"2021","journal-title":"Sci Bull (beijing)"},{"issue":"1","key":"10.1016\/j.bcp.2026.117791_b0360","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1080\/14756366.2020.1801672","article-title":"Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro","volume":"35","author":"Jo","year":"2020","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bcp.2026.117791_b0365","doi-asserted-by":"crossref","unstructured":"Chauhan, A. and S. Kalra, Identification of potent COVID-19 main protease (MPRO) inhibitors from flavonoids. PREPRINT (Version 1), 2020.","DOI":"10.21203\/rs.3.rs-34497\/v1"},{"issue":"20","key":"10.1016\/j.bcp.2026.117791_b0370","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222011069","article-title":"Promising Antiviral Activities of Natural Flavonoids against SARS-CoV-2 Targets: Systematic Review","volume":"22","author":"Kaul","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.117791_b0375","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1038\/s41467-021-23751-3","article-title":"Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease","volume":"12","author":"Su","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.117791_b0380","doi-asserted-by":"crossref","unstructured":"Zhong, B.A.-O., et al., Oridonin Inhibits SARS-CoV-2 by Targeting Its 3C-Like Protease. (2688-4046 (Electronic)).","DOI":"10.1002\/smsc.202270012"},{"issue":"3","key":"10.1016\/j.bcp.2026.117791_b0385","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1021\/acs.jnatprod.5b00947","article-title":"Feeling Nature\u2019s PAINS: Natural Products, Natural Product drugs, and Pan Assay Interference Compounds (PAINS)","volume":"79","author":"Baell","year":"2016","journal-title":"J. Nat. Prod."},{"issue":"8","key":"10.1016\/j.bcp.2026.117791_b0390","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nchembio.1858","article-title":"Catalytic in vivo protein knockdown by small-molecule PROTACs","volume":"11","author":"Bondeson","year":"2015","journal-title":"Nat. Chem. Biol."},{"issue":"12","key":"10.1016\/j.bcp.2026.117791_b0395","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1080\/17460441.2019.1659242","article-title":"PROTACs\u2013 a game-changing technology","volume":"14","author":"Konstantinidou","year":"2019","journal-title":"Expert Opin. Drug Discovery"},{"issue":"8","key":"10.1016\/j.bcp.2026.117791_b0400","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.chembiol.2020.07.020","article-title":"PROTACs: an Emerging Therapeutic Modality in Precision Medicine","volume":"27","author":"Nalawansha","year":"2020","journal-title":"Cell Chem. Biol."},{"issue":"3","key":"10.1016\/j.bcp.2026.117791_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellin.2023.100092","article-title":"Antiviral PROTACs: Opportunity borne with challenge","volume":"2","author":"Liang","year":"2023","journal-title":"Cell Insight"},{"issue":"8","key":"10.1016\/j.bcp.2026.117791_b0410","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.1021\/acs.jmedchem.3c02416","article-title":"Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease","volume":"67","author":"Alugubelli","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.117791_b0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116202","article-title":"Design, synthesis, and biological evaluation of first-in-class indomethacin-based PROTACs degrading SARS-CoV-2 main protease and with broad-spectrum antiviral activity","volume":"268","author":"Desantis","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.117791_b0420","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1038\/s41467-025-59922-9","article-title":"Identification of naturally occurring drug-resistant mutations of SARS-CoV-2 papain-like protease","volume":"16","author":"Tan","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2026.117791_b0425","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1038\/s41467-025-59870-4","article-title":"A novel, covalent broad-spectrum inhibitor targeting human coronavirus Mpro","volume":"16","author":"Sun","year":"2025","journal-title":"Nat. Commun."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522600122X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522600122X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:07:35Z","timestamp":1777446455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000629522600122X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":85,"alternative-id":["S000629522600122X"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117791","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From 2020 to 2025: Comprehensive review Decoding novel structural inhibitors for Mpro of SARS-CoV-2","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117791","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117791"}}